{
    "messages": [
        {
            "role": "system",
            "content": "\nYou are a helpful biological data assistant assigned with the task of constructing specialized biological dataset and biological data processing.\nTo achieve this, you will be using an interactive coding environment equipped with a variety of tool functions, data, and softwares to assist you throughout the process.\n\nGiven a task, make a plan first. The plan should be a numbered list of steps that you will take to solve the task. Be specific and detailed.\nFormat your plan as a checklist with empty checkboxes like this:\n1. [ ] First step\n2. [ ] Second step\n3. [ ] Third step\n\nFollow the plan step by step. After completing each step, update the checklist by replacing the empty checkbox with a checkmark:\n1. [\u2713] First step (completed)\n2. [ ] Second step\n3. [ ] Third step\n\nIf a step fails or needs modification, mark it with an X and explain why:\n1. [\u2713] First step (completed)\n2. [\u2717] Second step (failed because...)\n3. [ ] Modified second step\n4. [ ] Third step\n\nAlways show the updated plan after each step so the user can track progress.\n\nAt each turn, you should first provide your thinking and reasoning given the conversation history.\nAfter that, you have two options:\n\n1) Interact with a programming environment. Your code should be enclosed using \"<execute>\" tag, for example: <execute> print(\"Hello World!\") </execute>. IMPORTANT: You must end the code block with </execute> tag.\n   - For Python code (default): <execute> print(\"Hello World!\") </execute>\n   - For R code: <execute> #!R\nlibrary(ggplot2)\nprint(\"Hello from R\") </execute>\n   - For Bash scripts and commands: <execute> #!BASH\necho \"Hello from Bash\"\nls -la </execute>\n   - For CLI softwares, use Bash scripts.\n   \n2) When you think it is ready, directly provide a solution that adheres to the required format for the given task to the user. Your solution should be enclosed using \"<solution>\" tag, for example: The answer is <solution> A </solution>. IMPORTANT: You must end the solution block with </solution> tag.\n\nYou can only chose one option one time.\n\nYou have many chances to interact with the environment to receive the observation. So you can decompose your code into multiple steps.\nDon't overcomplicate the code. Keep it simple and easy to understand.\nWhen writing the code, please print out the steps and results in a clear and concise manner, like a research log.\nWhen calling the existing python functions in the function dictionary, YOU MUST SAVE THE OUTPUT and PRINT OUT the result.\nFor example, result = understand_scRNA(XXX) print(result)\nOtherwise the system will not be able to know what has been done.\n\nFor R code, use the #!R marker at the beginning of your code block to indicate it's R code.\nFor Bash scripts and commands, use the #!BASH marker at the beginning of your code block. This allows for both simple commands and multi-line scripts with variables, loops, conditionals, loops, and other Bash features.\n\nIn each response, you must include EITHER <execute> or <solution> tag. Not both at the same time. Do not respond with messages without any tags. No empty messages.\n\nYou could finish the task based on current environment and you must not install new version packges as it will destory the environment !!!\nYou could finish the task based on current environment and you must not install new version packges as it will destory the environment !!!\nYou could finish the task based on current environment and you must not install new version packges as it will destory the environment !!!\n\n\n\nEnvironment Resources:\n\n- Function Dictionary:\nBased on your query, I've identified the following most relevant functions that you can use in your code:\n---\nImport file: assistant.tool_biodatalab.support_tools\n====================================================\nMethod: read_function_source_code\n  Description: Read the source code of a function from any module path.\n  Required Parameters:\n    - function_name (str): Fully qualified function name (e.g., 'bioagentos.tool.support_tools.write_python_code') [Default: None]\n\n\n---\n\nIMPORTANT: When using any function, you MUST first import it from its module. For example:\nfrom [module_name] import [function_name]\n\n- Biological data lake\nYou can access a biological data lake at the following path: ./operation_env/database_lake.\nBased on your query, I've identified the following most relevant datasets:\nEach item is listed with its description to help you understand its contents.\n----\n\n----\n\n- Software Library:\nBased on your query, I've identified the following most relevant libraries that you can use:\nEach library is listed with its description to help you understand its functionality.\n----\npdfplumber:\n  [Python Package] Plumb a PDF for detailed information about each text character,\n  rectangle, and line (Essential for reading papers).\npytesseract:\n  [Python Package] Python-tesseract is an optical character recognition (OCR) tool\n  for python.\npillow:\n  [Python Package] The Python Imaging Library adds image processing capabilities\n  to your Python interpreter.\nbeautifulsoup4:\n  [Python Package] Screen-scraping library to extract data from HTML and XML\n  files.\nbiopython: [Python Package] A set of freely available tools for biological computation.\nrdkit: [Python Package] A collection of cheminformatics and machine learning software.\nlangchain: [Python Package] Building applications with LLMs through composability.\ntransformers:\n  [Python Package] State-of-the-art Machine Learning for Pytorch, TensorFlow, and\n  JAX.\nscikit-learn: [Python Package] Simple and efficient tools for predictive data analysis.\nopenai: [Python Package] The OpenAI Python library.\nanthropic: [Python Package] The Anthropic Python library.\ngoogle-genai: [Python Package] Google Generative AI SDK.\ntidyverse:\n  [R Package] A collection of R packages designed for data science (ggplot2,\n  dplyr, tidyr, readr, etc.).\ndata.table: [R Package] Fast aggregation of large data.\n----\n\n- Note on using R packages and Bash scripts:\n  - R packages: Use subprocess.run(['Rscript', '-e', 'your R code here']) in Python, or use the #!R marker in your execute block.\n  - Bash scripts and commands: Use the #!BASH marker in your execute block for both simple commands and complex shell scripts with variables, loops, conditionals, etc.\n        "
        },
        {
            "role": "user",
            "content": "# Core Task\nExtract detailed pharmacological information about Antibody-Drug Conjugates (ADCs) from the literature, specifically identifying Key fields including ADC Name, Conjugate Type, Drug-Antibody Ratio (DAR), mAb, Linker, Payload, and Drug Status.\nLiterature to analyze: `dataset/ADCdb/ref2.pdf`, `dataset/ADCdb/ref4.pdf`, `dataset/ADCdb/ref5.pdf`\n\n# Output Requirements & File Path\n- Output format: A CSV file with the following columns (exactly matching the ground truth CSV headers). Use \"N/A\" for missing values.\n  - `Paper`: The reference ID or filename of the paper (e.g., ref1).\n  - `ADC Name`: The name of the Antibody-Drug Conjugate.\n  - `mAb`: The specific monoclonal antibody used.\n  - `Linker`: The type of linker used to connect the antibody and payload.\n  - `Payload`: The cytotoxic payload delivered by the ADC.\n  - `Conjugate Type`: The method or type of conjugation.\n  - `DAR`: The Drug-Antibody Ratio.\n  - `Drug Status`: The current clinical or development status of the ADC.\n- Save Path: Save the result to: `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv`\n- Intermediate Storage Path: All intermediate code generated during execution, downloaded files, and temporary results must be stored in `/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/adcdb_extract/`\n\n# Output Example (For Reference Only)\nPaper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status\nref2,Pseudo-ADC-X,Anti-Target-Y IgG1,Enzymatic linker,Cytotoxin Z,Site-specific,3.8,Phase 3\nref4,NextGen-ADC,Bispecific mAb,pH-sensitive linker,Potent Payload A,Cysteine conjugation,N/A,Preclinical\n"
        },
        {
            "role": "assistant",
            "content": "I'll start by creating a plan to extract ADC pharmacological information from the literature.\n\n**Plan:**\n1. [ ] Check if the PDF files exist and verify their paths\n2. [ ] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf\n3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)\n4. [ ] Create a structured dataset with the extracted information\n5. [ ] Save the results to the specified CSV file path\n\nLet me start by checking the files and reading them:\n\n<execute>\nimport os\nimport pdfplumber\nimport pandas as pd\n\n# Define paths\npdf_paths = [\n    \"dataset/ADCdb/ref2.pdf\",\n    \"dataset/ADCdb/ref4.pdf\",\n    \"dataset/ADCdb/ref5.pdf\"\n]\n\n# Check if files exist\nfor path in pdf_paths:\n    if os.path.exists(path):\n        print(f\"Found: {path}\")\n    else:\n        print(f\"NOT found: {path}\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>NOT found: dataset/ADCdb/ref2.pdf\nNOT found: dataset/ADCdb/ref4.pdf\nNOT found: dataset/ADCdb/ref5.pdf\n</observation>"
        },
        {
            "role": "assistant",
            "content": "Let me check the database lake structure to find the correct paths:\n\n<execute>\nimport os\n\n# Check database lake\nbase_path = \"./operation_env/database_lake\"\nprint(\"Checking database lake...\")\nfor root, dirs, files in os.walk(base_path):\n    for file in files:\n        if \"ref\" in file.lower() and \".pdf\" in file.lower():\n            print(os.path.join(root, file))\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Checking database lake...\n</observation>"
        },
        {
            "role": "assistant",
            "content": "<execute>\nimport os\n\n# Check current directory and look for dataset folder\nprint(\"Current directory:\", os.getcwd())\nprint(\"\\nLooking for dataset folder...\")\nif os.path.exists(\"dataset\"):\n    for root, dirs, files in os.walk(\"dataset\"):\n        for file in files:\n            if \".pdf\" in file:\n                print(os.path.join(root, file))\nelse:\n    print(\"dataset folder not found\")\n\n# Also check root\nprint(\"\\nChecking /root...\")\nif os.path.exists(\"/root\"):\n    for item in os.listdir(\"/root\"):\n        print(f\"  {item}\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Current directory: /root/biodatalab\n\nLooking for dataset folder...\ndataset folder not found\n\nChecking /root...\n  .bashrc\n  .profile\n  autodl-fs\n  autodl-pub\n  .cache\n  .codex\n  .conda\n  .config\n  .dotnet\n  .ipython\n  .java\n  .jupyter\n  .local\n  .mamba\n  .mem0\n  .ncbi\n  .nv\n  .nvm\n  .parallel\n  .ssh\n  .tooluniverse\n  .vscode-R\n  .vscode-server\n  autodl-tmp\n  biodatalab\n  miniconda3\n  nltk_data\n  tf-logs\n  .bash_history\n  .condarc\n  .prodyrc\n  .python_history\n  .viminfo\n  .wget-hsts\n  .zshrc\n  ncbi_error_report.txt\n</observation>"
        },
        {
            "role": "assistant",
            "content": "<execute>\nimport os\n\n# Check autodl-tmp folder\ntmp_path = \"/root/autodl-tmp\"\nif os.path.exists(tmp_path):\n    print(\"autodl-tmp exists\")\n    for item in os.listdir(tmp_path):\n        print(f\"  {item}\")\n        \n# Also check biodatalab\nprint(\"\\nChecking biodatalab...\")\nbio_path = \"/root/biodatalab\"\nif os.path.exists(bio_path):\n    for item in os.listdir(bio_path):\n        print(f\"  {item}\")\n        if os.path.isdir(os.path.join(bio_path, item)):\n            for subitem in os.listdir(os.path.join(bio_path, item)):\n                print(f\"    {subitem}\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>autodl-tmp exists\n  .autodl\n  biomni_v20260207_bash_log\n  biomni_v20260207_evaluate_results\n  biomni_v20260207_log\n  biomni_v20260207_pred_results\n  biomni_v20260207_tmp\n  biomni_v20260208_bash_log\n  biomni_v20260208_evaluate_results\n  biomni_v20260208_log\n  biomni_v20260208_pred_results\n  biomni_v20260208_tmp\n  mBodyMap\n  resource\n  hg19ToHg38.over.chain.gz\n  biomni_v20250208_pred_results\n\nChecking biodatalab...\n  assistant\n    __pycache__\n    agent\n    biorxiv_scripts\n    commons\n    model\n    prompts\n    task\n    tool_biodatalab\n    tool_biomni\n    __init__.py\n    env_desc_biodatalab.py\n    env_desc_biomni.py\n    interface.py\n    llm.py\n    utils.py\n    version.py\n  benchmark\n    dataset\n    gold_programs\n    gold_results\n    tasks\n    verifiers\n    README.md\n    biodatalab.csv\n    biodatalab_new.csv\n    update_verified_tasks.py\n    verified_task.json\n  data\n    pbmc3k_processed.h5ad\n  evaluate_bash_scripts\n    run_evaluate_batch_biomni_claude-haiku-4-5.sh\n    run_evaluate_batch_biomni_claude-opus-4-5.sh\n    run_evaluate_batch_biomni_doubao_seed_1_8.sh\n    run_evaluate_batch_biomni_dpsk_v3_2.sh\n    run_evaluate_batch_biomni_gemini-3-flash-preview.sh\n    run_evaluate_batch_biomni_gemini-3-pro-preview.sh\n    run_evaluate_batch_biomni_glm_4_7.sh\n    run_evaluate_batch_biomni_gpt_5_1.sh\n    run_evaluate_batch_biomni_gpt_5_2.sh\n    run_evaluate_batch_biomni_kimi_2_5.sh\n    run_evaluate_batch_biomni_qwen3_max.sh\n  evaluate_results\n    claude-haiku-4-5\n    claude-opus-4-5\n    deepseek-v3.2-fast\n    doubao-seed-1-8\n    gemini-3-flash-preview\n    gemini-3-pro-preview\n    glm-4.7\n    gpt-5.1\n    grok-4-1-fast-reasoning\n    kimi-k2.5\n    qwen3-max-2026-01-23\n  log\n    claude-haiku-4-5\n    claude-opus-4-5\n    deepseek-v3.2-fast\n    doubao-seed-1-8\n    gemini-3-flash-preview\n    gemini-3-pro-preview\n    glm-4.7\n    gpt-5.1\n    grok-4-1-fast-reasoning\n    kimi-k2.5\n    qwen3-max-2026-01-23\n  mapper_logs\n    mapper.log_734457_1770451996\n  operation_env\n    BatMeth2-master\n    MethHaplo-main\n    SAAMBE-3D-master\n  paper_analysis\n    analysis_100_tasks.py\n  pred_results\n    type\n    GSE116315_family.soft.gz\n    adcdb_extract_1.csv\n    adcdb_extract_2.json\n    antibody_seq_retrieval.fasta\n    asmdb_retrieval.json\n    atlas_retrieval_1.json\n    bioka_retrieval.json\n    cds_db_retrieval.json\n    circmine_extract.csv\n    circmine_retrieval.json\n    cov_pdb_retrieval.json\n    covpdb_integration_complex.csv\n    covpdb_integration_protein.csv\n    crost_retrieval.json\n    ctr_db_retrieval.json\n    cyanoimicsdb_extract.tsv\n    cyanoomicsdb_extract.csv\n    dda_extract.csv\n    ddinter_retrieval.json\n    disco_extract.csv\n    dntppooldb_extract.csv\n    fusionneoantigen_extract.json\n    macc_extract.csv\n    npcdr_extract_1.json\n    npcdr_extract_2.csv\n    npcdr_retrieval.json\n    paper.txt\n    pcmdb_extract.csv\n    pharmgwas_extract.csv\n    pronab_extract.csv\n    ravar_extract.json\n    rmsf_ca.json\n    scan_retrieval.json\n    scqtlbase_retrieval.json\n    stemdriver_retrieval.json\n    stemdriver_retrieval_temp.json\n    tf_marker_retrieval.json\n    themarker_extract_1.json\n    themarker_extract_2.csv\n  pred_results_new\n    claude-haiku-4-5\n    claude-opus-4-5\n    deepseek-v3.2-fast\n    doubao-seed-1-8\n    gemini-3-flash-preview\n    gemini-3-pro-preview\n    glm-4.7\n    gpt-5.1\n    grok-4-1-fast-reasoning\n    kimi-k2.5\n    qwen3-max-2026-01-23\n  tmp\n    adcdb_extract\n    asmdb_retrieval\n    atlas\n    bioka_retrieval\n    cds_db_retrieval\n    circmine_extract\n    circmine_retrieval\n    covpdb\n    crost_retrieval\n    ctr_db_retrieval\n    dda_extract\n    ddinter_retrieval\n    disco_extract\n    dntppooldb_extract\n    fusionneoantigen_extract\n    macc_extract\n    npcdr_extract_1\n    npcdr_extract_2\n    npcdr_retrieval\n    pcmdb_extract\n    pharmgwas_extract\n    pronab_extract\n    ravar_extract\n    scan_retrieval\n    scqtlbase_retrieval\n    stemdriver_retrieval\n    test_pdb\n    tf_marker_retrieval\n    themarker_extract_1\n    themarker_extract_2\n    analyze_covalent.py\n    analyze_covalent_v2.py\n    download_pdbs.py\n    download_pdbs_batch.py\n    ecod.domains.txt\n    entries.idx\n    fetch_all_pdbs.py\n    get_pdb_list.py\n    parse_idx.py\n    pdb_candidates.json\n    pdb_ids.json\n    query.json\n    query_pdb.py\n    query_test.py\n  tmp_new\n    claude-haiku-4-5\n    claude-opus-4-5\n    deepseek-v3.2-fast\n    doubao-seed-1-8\n    gemini-3-flash-preview\n    gemini-3-flash-previewpcmdb\n    gemini-3-pro-preview\n    gemini-3-pro-previewpcmdb\n    glm-4.7\n    gpt-5.1\n    grok-4-1-fast-reasoning\n    kimi-k2.5\n    qwen3-max-2026-01-23\n  traitdata\n    R\n    data-raw\n    data\n    man\n    vignettes\n    .Rbuildignore\n    .gitignore\n    DESCRIPTION\n    LICENSE.md\n    NAMESPACE\n    README.Rmd\n    README.md\n    traitdata.Rproj\n  .env.template\n  README.md\n  elton_birds_species_list.csv\n  env_install.sh\n  environment.yaml\n  environment.yml\n  example_log_trajectory.json\n  example_log_trajectory_zjt.json\n  output.pdbqt\n  process_pdbs.py\n  retrieve_cyano.py\n  run_evaluate_batch_biomni.py\n  run_evaluate_batch_biomni.sh\n  get_gwas.py\n  run_evaluate_batch_biomni_for_bash.py\n  run_evaluate_case_biomni.py\n  run_evaluate_case_stella.py\n  run_evaluate_case_tooluniverse.py\n  run_only_evaluate.py\n  run_qc_filtering.py\n  1crn.pdb.gz\n  run_qc_filtering_corrected.py\n  count_genes.py\n  5yuv.pdb.gz\n  run_qc_filtering_corrected_v2.py\n  6a1f.pdb.gz\n  6a1g.pdb.gz\n  run_qc_filtering_corrected_v3.py\n  run_qc_filtering_final.py\n  script.py\n  metadata_script.py\n  sasa_script.py\n  sasa_script_v2.py\n  process_drugs.py\n  search_geo.py\n  search_sra.py\n  search_geo_v2.py\n  final_extraction.py\n  SRR31029759.sorted.bam\n  fix_sra_extraction.py\n  raw_counts_htseq.txt\n  debug_extraction.py\n  robust_search.py\n  simple_search.py\n  exhaustive_search.py\n  fix_sra_linking.py\n  GSE210066_metadata.csv\n  manual_check_gse.py\n  GSE210066_metadata_fixed.csv\n  fix_sra_search.py\n  final_sra_search.py\n  tmp.json\n  temp.json\n  fix_final_v2.py\n  retrieve_srrs.py\n  GSE210066_cell_stats.csv\n  ultimate_search.py\n  search_af_2025.py\n</observation>"
        },
        {
            "role": "assistant",
            "content": "<execute>\nimport os\n\n# Check benchmark/dataset\nbenchmark_dataset = \"/root/biodatalab/benchmark/dataset\"\nprint(\"Checking benchmark/dataset...\")\nfor item in os.listdir(benchmark_dataset):\n    print(f\"  {item}\")\n    if \"adc\" in item.lower():\n        adc_path = os.path.join(benchmark_dataset, item)\n        print(f\"\\nFound ADC folder: {adc_path}\")\n        for root, dirs, files in os.walk(adc_path):\n            for file in files:\n                print(f\"    {os.path.join(root, file)}\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Checking benchmark/dataset...\n  ADCdb\n\nFound ADC folder: /root/biodatalab/benchmark/dataset/ADCdb\n    /root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf\n    /root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf\n    /root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf\n  ASMdb\n  ATLAS\n  BioKA\n  COLOCdb\n  COVID-19\n  CancerMIRNome\n  CancerProteome\n  CancerSCEM\n  CellCommuNet\n  CellSTAR\n  ClinicalOmicsDB\n  CompoDynamics\n  CovPDB\n  CyanoOmicsDB\n  DDA\n  DDInter\n  DIANA-miTED\n  DISCO\n  DRMef\n  FusionNeoAntigen\n  GPEdit\n  Kincore\n  M2OR\n  MVIP\n  MetazExp\n  NPCDR\n  OncoDB\n  PCMDB\n  PGS-Depot\n  PLAbDab\n  PlantPAD\n  PncsHub\n  ProNAB\n  RAVAR\n  SCoV2-MD\n  SCovid\n  TF-Marker\n  TheMarker\n  VarEPS\n  ViMIC\n  dNTPpoolDB\n  iNClusive\n  mBodyMap\n  scAPAatlas\n  scQTLbase\n</observation>"
        },
        {
            "role": "assistant",
            "content": "**Updated Plan:**\n1. [\u2713] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)\n2. [ ] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf\n3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)\n4. [ ] Create a structured dataset with the extracted information\n5. [ ] Save the results to the specified CSV file path\n\nNow let me extract text from all three PDF files:\n\n<execute>\nimport pdfplumber\nimport os\n\n# Correct paths\npdf_paths = {\n    \"ref2\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf\",\n    \"ref4\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf\",\n    \"ref5\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf\"\n}\n\n# Extract text from each PDF\npdf_texts = {}\n\nfor ref, path in pdf_paths.items():\n    print(f\"\\n{'='*60}\")\n    print(f\"Extracting text from {ref}.pdf...\")\n    print(f\"{'='*60}\")\n    \n    text_content = []\n    with pdfplumber.open(path) as pdf:\n        print(f\"Total pages: {len(pdf.pages)}\")\n        for i, page in enumerate(pdf.pages):\n            text = page.extract_text()\n            if text:\n                text_content.append(f\"--- Page {i+1} ---\\n{text}\")\n    \n    full_text = \"\\n\\n\".join(text_content)\n    pdf_texts[ref] = full_text\n    print(f\"\\nFirst 3000 characters of {ref}.pdf:\")\n    print(full_text[:3000])\n    print(f\"\\n... (Total length: {len(full_text)} characters)\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>\n============================================================\nExtracting text from ref2.pdf...\n============================================================\nTotal pages: 1\n\nFirst 3000 characters of ref2.pdf:\n--- Page 1 ---\nHEMATOLOGIC MALIGNANCIES\u2014LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA\nTPS7589 Poster Session\nwaveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclo-\nphosphamide,doxorubicin,andprednisoneplusrituximab(R-CHP)inpreviouslyuntreated\ndiffuse large B-cell lymphoma (DLBCL).\nDavid Lavie, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Eva Gonza\u00b4lez Barca, Tae Min Kim,\nBenedettaPuccini,SiruoWang,RushdiaYusuf,PatriciaMarinello,WonSeogKim;HadassahMedical\nCenter,Jerusalem,Israel;AnkaraUniversitySchoolofMedicine,Ankara,Turkey;MariaSklodowska-\nCurieNationalResearchInstituteofOncology,Warsaw,Poland;InstitutCatala` d\u2019OncologiaHospitalet,\nBarcelona University, IDIBELL, Barcelona, Spain; Seoul National University Hospital, Seoul, South\nKorea; Unit AOU Careggi, Florence, Italy; Merck & Co., Inc., Rahway, NJ; Samsung Medical Center,\nSeoul, South Korea\nBackground:Thepreferredfirst-lineregimenforDLBCLisrituximabwithcyclophosphamide,doxoru-\nbicin,vincristine,andprednisone(R-CHOP);butnoveltherapiesareneeded.Arecentphase3study\nshowedthatreplacingvincristinewithanantibody-drugconjugate(ADC)isaviableapproach(TillyH\netal.NEnglJMed.2022;386:351-363).Receptortyrosinekinase\u2013likeorphanreceptor1(ROR1)is\nanoncofetalproteinthatisminimallyexpressedinadulttissuesandoverexpressedinDLBCL.ZVisan\nADCcomprisingahumanizedIgG1monoclonalanti-ROR1,aproteolyticallycleavablelinker,andthe\nantimicrotubuleagent,monomethylauristatinE.Thesingle-arm,open-label,phase2waveLINE-007\nstudy(NCT05406401)willinvestigateZVcombinedwithR-CHPinpatientswithpreviouslyuntreated\nDLBCL.Part1isbeingconductedtodeterminesafetyandtolerabilityandrecommendedphase2dose\n(RP2D)ofZVincombinationwithR-CHP.Part2willbeconductedtoinvestigateefficacyofZVatthe\nRP2DwithR-CHP.Methods:Eligiblepatientswillbe$18yearsofageandhavepreviouslyuntreated\nhistologically confirmed DLBCL, positron emission tomography (PET)\u2013positive disease verified by\nblinded independent central review (BICR), an ECOG PS of 0 or 1, and adequate organ function.\nPatients diagnosed with primary mediastinal B-cell lymphoma, with a history of transformation of\nindolentdiseasetoDLBCL,oractivecentralnervoussystemlymphomawillbeexcluded.Approximately\n60patientswillbeenrolled(part1,n=45;part2,n=15).Part1willuseamodifiedtoxicityprobability\nintervaldesigntoestablishtheRP2DofZVwhenadministeredwithR-CHP.ThestartingdoseofZVwill\nbe1.75mg/kg(modifiedto1.5,2.0,2.25,or2.5mg/kg)administeredasanintravenousinfusionevery\n3weeks(Q3W)incombinationwithR-CHP.Inpart2,anadditional15patientswillreceiveZVatRP2D\nplusR-CHPQ3Wforupto6cyclesuntildiseaseprogressionperLugano2014criteria,unacceptable\ntoxicity, or withdrawal. Disease response assessment, computed tomography, and PET will occur at\nbaselineandcycles3and6.Adverseevents(AEs)willbemonitoredupto30daysaftercessationof\ntreatment(90daysforseriousAEs,or30daysifnewanticancertherapyisinitiated).AEswillbegraded\nper National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Primary\nend points a\n\n... (Total length: 3821 characters)\n\n============================================================\nExtracting text from ref4.pdf...\n============================================================\nTotal pages: 1\n\nFirst 3000 characters of ref4.pdf:\n--- Page 1 ---\nDEVELOPMENTAL THERAPEUTICS\u2014MOLECULARLYTARGETEDAGENTSAND TUMOR BIOLOGY\n3001 Oral Abstract Session\nBL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in pa-\ntientswithlocallyadvancedormetastaticsolidtumor:Resultsfromafirst-in-humanphase\n1 study.\nLi Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang,\nLikun Chen, Xue Hou, Wen Zou, Muran Ding, Jing Yu, Suoyu Zhang, Junxian Wang, Sa Xiao,\nHongwei Wang, Hai Zhu, Martin Sebastian Olivo, Yi Zhu; Department of Medical Oncology, State\nKeyLaboratoryofOncologyinSouthChina;CollaborativeInnovationCenterforCancerMedicine,Sun\nYat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Clinical Research,\nSunYat-senUniversityCancerCenter,StateKeyLaboratoryofOncologyinSouthChina,Collaborative\nInnovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma\nDiagnosis and Therapy, Guangz, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen\nUniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation\nCenter for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen\nUniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation\nCenter for Cancer Medicine, Guangzhou, Guangdong, China; Department of Clinical Research, Sun\nYat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative\nInnovationCenterforCancerMedicine,Guangzhou,China;MedicalOncologyDepartment,SunYat-sen\nUniversity Cancer Center, Guangzhou, China; Dept. of Medical Oncology, Sun Yat-Sen University,\nGuangzhou, China; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Baili-Bio\n(Chengdu)PharmaceuticalCo.,Ltd.,Chengdu,China;Bailipharm,ChengduSichuan,China;Sichuan\nBaili-pharmaceuticalco.,LTD,Redmond,WA; SystImmune, Inc., Redmond,WA; SytImmune, INC.,\nRedmond, WA\nBackground: BL-B01D1isafirst-in-classnovelADCconsistingofanEGFRxHER3bispecificantibody\nlinkedtoanovelTOP-Iinhibitorpayloadviaacleavablelinker.Wenowpresentsafety/efficacyresults\nfrom a FIH phase I study of BL-B01D1. Methods: This study included patients (pts) with locally\nadvancedormetastaticsolidtumors.Fordoseescalation(D-ESC,i3+3),BL-B01D1wasadministered\nintravenouslyatdosesof0.27,1.5,3.0mg/kgQW,2.5,3.0,3.5mg/kgD1D8Q3Wor4.5,5.0,6.0mg/\nkgD1Q3W.Asubsetofptswereenrolledintodose-expansion(D-EXP)atQ3Wregimens.Results: Asof\nDec31,2022,150ptswereenrolledandreceivedatleastonedose(D-ESC,n=25;D-EXP,n=125).\nDLTs were neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg\nD1D8Q3W.TheMTDsweredeterminedtobe3.0mg/kgD1D8Q3Wand6.0mg/kgD1Q3W.D-EXPwas\ncarriedoutat2.5,3.0mg/kgD1D8Q3Wand4.5,5.0,6.0mg/kgD1Q3W.144ptswereenrolledacross\nall Q3W dose levels (D-ESC and D-EXP), including 89 NSCLC, 7 SCLC, 27 nasopharyngeal cancer\n(NPC),19HNSCCand2others.MostcommonTRAEs(.10%,allgrade/$G3)wereleukopenia(60%/\n30%),neutropenia(51%/34%),anemia(45%/15%),thro\n\n... (Total length: 4879 characters)\n\n============================================================\nExtracting text from ref5.pdf...\n============================================================\nTotal pages: 1\n\nFirst 3000 characters of ref5.pdf:\n--- Page 1 ---\nHEMATOLOGIC MALIGNANCIES\u2014LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA\nTPS7595 Poster Session\nwaveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as\nmonotherapy or in combination in patients (pts) with aggressive and indolent B-cell\nmalignancies.\nPierLuigiZinzani,JiriMayer,OhadBenjamini,AlejandroBerkovits,IngridGlimelius,DonA.Stevens,\nArvindChaudhry,AhmetMuzafferDemir,Ramo\u00b4nGarciaSanz,WonSeogKim,FeiLi,JanuszHalka,\nAna Marin-Niebla, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Armando Santoro, Yixin Ren, Uzor Ogbu,\nPatriciaMarinello,WojciechJurczak;IRCCSAziendaOspedaliero-UniversitariadiBolognaIstitutodi\nEmatologia\u201cSera`gnoli\u201d,Bologna,Italy;FakultniNemocniceBrnoBohunice-InterniHematologickaa\nOnkologicka Klinika, Brno, Czech Republic; Chaim Sheba Medical Center, Ramat Gan, Israel;\nInmunocel Chile, Santiago, Chile; Uppsala University and Akademiska sjukhuset-Blod-och tumor-\nsjukdomar,Uppsala,Sweden;NortonWomen\u2019sandChildren\u2019sHospital\u2013NortonCancerInstitute\u2013St.\nMatthews, Louisville, KY; Summit Cancer Centers, Spokane Valley, WA; Trakya University, Edirne,\nTurkey; Hospital Universitario de Salamanca \u2013 Complejo Asistencial Universitario de Salamanca,\nSalamanca, Spain; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul,\nSouth Korea; The First Affiliated Hospital of Nanchang University, Nanchang, China; Samodzielny\nPubliczny Zaklad Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii, Olsztyn,\nPoland;HospitalUniversitariValld\u2019Hebron,Barcelona,Spain;AnkaraUniversitySchoolofMedicine,\nAnkara, Turkey; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;\nHumanitasUniversity,PieveEmanuele,andIRCCSHumanitasResearchHospital\u2013HumanitasCancer\nCenter Rozzano, Milan, Italy; Merck & Co., Inc., Rahway, NJ; MSC National Research Institute of\nOncology, Krakow, Poland\nBackground:ROR1isatransmembraneproteinexpressedinhematologicmalignancies.Zilovertamab\nvedotin (ZV) is an antibody-drug conjugate comprising a humanized IgG1 monoclonal anti-ROR1, a\nproteolyticallycleavablelinker,andtheantimicrotubuleagentmonomethylauristatinE.Nemtabrutinib\nisareversibleinhibitorofBrutonstyrosinekinase(BTK).ThecombinationofZVandaBTKihasthe\npotentialforimprovedresponsesinB-cellmalignancies.ThewaveLINE-006study(NCT05458297)is\ndesignedtoinvestigatesafetyandefficacyofZVasmonotherapyorincombinationwithnemtabrutinib\nin pts with B-cell malignancies. Methods: Eligible pts are $18 years old with biopsy-proven and/or\nhistologically confirmed mantle cell lymphoma (MCL), Richter s transformation (RT), chronic lym-\nphocytic leukemia (CLL), or follicular lymphoma (FL), relapsed or refractory (R/R) disease, ECOG\nperformance status of 0 to 2, and adequate organ function (table). Approximately 275 pts will be\nenrolledin6cohorts(A-F;seetable).IncohortsAandB,patientswillreceiveZV2.5mg/kgIVQ3W.In\ncohortC,30patientswillbeenrolledinasafetyrun-inphaseofZVincombinationwithnemtabrutinib,\nthenanadditional15patientswillreceiveth\n\n... (Total length: 4910 characters)\n</observation>"
        },
        {
            "role": "assistant",
            "content": "**Updated Plan:**\n1. [\u2713] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)\n2. [\u2713] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf\n3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)\n4. [ ] Create a structured dataset with the extracted information\n5. [ ] Save the results to the specified CSV file path\n\nLet me analyze the full text from all PDFs to extract complete information:\n\n<execute>\nimport pdfplumber\nimport os\n\n# Re-extract full text from each PDF\npdf_paths = {\n    \"ref2\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf\",\n    \"ref4\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf\",\n    \"ref5\": \"/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf\"\n}\n\n# Get full texts\nfull_texts = {}\nfor ref, path in pdf_paths.items():\n    with pdfplumber.open(path) as pdf:\n        full_text = \"\"\n        for page in pdf.pages:\n            text = page.extract_text()\n            if text:\n                full_text += text + \"\\n\"\n        full_texts[ref] = full_text\n        print(f\"\\n{'='*70}\")\n        print(f\"FULL TEXT FROM {ref}.pdf:\")\n        print(f\"{'='*70}\")\n        print(full_text[:5000])\n        if len(full_text) > 5000:\n            print(f\"\\n... (continued, total length: {len(full_text)} chars)\")\n        print(f\"\\n{'='*70}\")\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>The output is too long to be added to context. Here are the first 10K characters...\n\n======================================================================\nFULL TEXT FROM ref2.pdf:\n======================================================================\nHEMATOLOGIC MALIGNANCIES\u2014LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA\nTPS7589 Poster Session\nwaveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclo-\nphosphamide,doxorubicin,andprednisoneplusrituximab(R-CHP)inpreviouslyuntreated\ndiffuse large B-cell lymphoma (DLBCL).\nDavid Lavie, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Eva Gonza\u00b4lez Barca, Tae Min Kim,\nBenedettaPuccini,SiruoWang,RushdiaYusuf,PatriciaMarinello,WonSeogKim;HadassahMedical\nCenter,Jerusalem,Israel;AnkaraUniversitySchoolofMedicine,Ankara,Turkey;MariaSklodowska-\nCurieNationalResearchInstituteofOncology,Warsaw,Poland;InstitutCatala` d\u2019OncologiaHospitalet,\nBarcelona University, IDIBELL, Barcelona, Spain; Seoul National University Hospital, Seoul, South\nKorea; Unit AOU Careggi, Florence, Italy; Merck & Co., Inc., Rahway, NJ; Samsung Medical Center,\nSeoul, South Korea\nBackground:Thepreferredfirst-lineregimenforDLBCLisrituximabwithcyclophosphamide,doxoru-\nbicin,vincristine,andprednisone(R-CHOP);butnoveltherapiesareneeded.Arecentphase3study\nshowedthatreplacingvincristinewithanantibody-drugconjugate(ADC)isaviableapproach(TillyH\netal.NEnglJMed.2022;386:351-363).Receptortyrosinekinase\u2013likeorphanreceptor1(ROR1)is\nanoncofetalproteinthatisminimallyexpressedinadulttissuesandoverexpressedinDLBCL.ZVisan\nADCcomprisingahumanizedIgG1monoclonalanti-ROR1,aproteolyticallycleavablelinker,andthe\nantimicrotubuleagent,monomethylauristatinE.Thesingle-arm,open-label,phase2waveLINE-007\nstudy(NCT05406401)willinvestigateZVcombinedwithR-CHPinpatientswithpreviouslyuntreated\nDLBCL.Part1isbeingconductedtodeterminesafetyandtolerabilityandrecommendedphase2dose\n(RP2D)ofZVincombinationwithR-CHP.Part2willbeconductedtoinvestigateefficacyofZVatthe\nRP2DwithR-CHP.Methods:Eligiblepatientswillbe$18yearsofageandhavepreviouslyuntreated\nhistologically confirmed DLBCL, positron emission tomography (PET)\u2013positive disease verified by\nblinded independent central review (BICR), an ECOG PS of 0 or 1, and adequate organ function.\nPatients diagnosed with primary mediastinal B-cell lymphoma, with a history of transformation of\nindolentdiseasetoDLBCL,oractivecentralnervoussystemlymphomawillbeexcluded.Approximately\n60patientswillbeenrolled(part1,n=45;part2,n=15).Part1willuseamodifiedtoxicityprobability\nintervaldesigntoestablishtheRP2DofZVwhenadministeredwithR-CHP.ThestartingdoseofZVwill\nbe1.75mg/kg(modifiedto1.5,2.0,2.25,or2.5mg/kg)administeredasanintravenousinfusionevery\n3weeks(Q3W)incombinationwithR-CHP.Inpart2,anadditional15patientswillreceiveZVatRP2D\nplusR-CHPQ3Wforupto6cyclesuntildiseaseprogressionperLugano2014criteria,unacceptable\ntoxicity, or withdrawal. Disease response assessment, computed tomography, and PET will occur at\nbaselineandcycles3and6.Adverseevents(AEs)willbemonitoredupto30daysaftercessationof\ntreatment(90daysforseriousAEs,or30daysifnewanticancertherapyisinitiated).AEswillbegraded\nper National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Primary\nend points are safety and tolerability and RP2D for ZV in combination with R-CHP, and complete\nresponse rate per Lugano 2014 criteria as assessed by the investigator. Secondary end points are\nobjective response rate and duration of response per Lugano 2014 criteria by investigator review.\nExploratoryendpointsincludeprogression-freesurvivalperLugano2014criteriabyBICRandoverall\nsurvival. Recruitment is currently underway. Clinical trial information: NCT05406401. Research\nSponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.\n\u00a92023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.\n331.111.300.291\nmorf\n6202\n,13\nyraunaJ\nno\n331.111.3.291\nyb\ngro.sbupocsa\nmorf\ndedaolnwoD\n.devreser\nsthgir\nllA\n.ygolocnO\nlacinilC\nfo\nyteicoS\nnaciremA\n6202\n\u00a9\nthgirypoC\n\n\n======================================================================\n\n======================================================================\nFULL TEXT FROM ref4.pdf:\n======================================================================\nDEVELOPMENTAL THERAPEUTICS\u2014MOLECULARLYTARGETEDAGENTSAND TUMOR BIOLOGY\n3001 Oral Abstract Session\nBL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in pa-\ntientswithlocallyadvancedormetastaticsolidtumor:Resultsfromafirst-in-humanphase\n1 study.\nLi Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang,\nLikun Chen, Xue Hou, Wen Zou, Muran Ding, Jing Yu, Suoyu Zhang, Junxian Wang, Sa Xiao,\nHongwei Wang, Hai Zhu, Martin Sebastian Olivo, Yi Zhu; Department of Medical Oncology, State\nKeyLaboratoryofOncologyinSouthChina;CollaborativeInnovationCenterforCancerMedicine,Sun\nYat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Clinical Research,\nSunYat-senUniversityCancerCenter,StateKeyLaboratoryofOncologyinSouthChina,Collaborative\nInnovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma\nDiagnosis and Therapy, Guangz, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen\nUniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation\nCenter for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen\nUniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation\nCenter for Cancer Medicine, Guangzhou, Guangdong, China; Department of Clinical Research, Sun\nYat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative\nInnovationCenterforCancerMedicine,Guangzhou,China;MedicalOncologyDepartment,SunYat-sen\nUniversity Cancer Center, Guangzhou, China; Dept. of Medical Oncology, Sun Yat-Sen University,\nGuangzhou, China; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Baili-Bio\n(Chengdu)PharmaceuticalCo.,Ltd.,Chengdu,China;Bailipharm,ChengduSichuan,China;Sichuan\nBaili-pharmaceuticalco.,LTD,Redmond,WA; SystImmune, Inc., Redmond,WA; SytImmune, INC.,\nRedmond, WA\nBackground: BL-B01D1isafirst-in-classnovelADCconsistingofanEGFRxHER3bispecificantibody\nlinkedtoanovelTOP-Iinhibitorpayloadviaacleavablelinker.Wenowpresentsafety/efficacyresults\nfrom a FIH phase I study of BL-B01D1. Methods: This study included patients (pts) with locally\nadvancedormetastaticsolidtumors.Fordoseescalation(D-ESC,i3+3),BL-B01D1wasadministered\nintravenouslyatdosesof0.27,1.5,3.0mg/kgQW,2.5,3.0,3.5mg/kgD1D8Q3Wor4.5,5.0,6.0mg/\nkgD1Q3W.Asubsetofptswereenrolledintodose-expansion(D-EXP)atQ3Wregimens.Results: Asof\nDec31,2022,150ptswereenrolledandreceivedatleastonedose(D-ESC,n=25;D-EXP,n=125).\nDLTs were neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg\nD1D8Q3W.TheMTDsweredeterminedtobe3.0mg/kgD1D8Q3Wand6.0mg/kgD1Q3W.D-EXPwas\ncarriedoutat2.5,3.0mg/kgD1D8Q3Wand4.5,5.0,6.0mg/kgD1Q3W.144ptswereenrolledacross\nall Q3W dose levels (D-ESC and D-EXP), including 89 NSCLC, 7 SCLC, 27 nasopharyngeal cancer\n(NPC),19HNSCCand2others.MostcommonTRAEs(.10%,allgrade/$G3)wereleukopenia(60%/\n30%),neutropenia(51%/34%),anemia(45%/15%),thrombocytopenia(44%/19%),alopecia(30%/\n0%), nausea (29%/,1%), vomiting (28%/0%), asthenia (21%/,1%), decreased appetite (22%/\n,1%),asthenia(21%/,1%),hypophagia(16%/0%),diarrhoea(15%/2%), mouth ulceration (15%/\n,1%), rash (13%/0%). No ILD was observed. 122 pts were evaluable for efficacy (at least 1 tumor\nassessment). PK and other details will be updated in the meeting. Conclusions: BL-B01D1 demon-\nstratedencouragingefficacyinheavilypretreatedmetastatic/locallyadvancedsolidtumors,especially\nin pts with EGFRm NSCLC. The safety profile showed adequate safety and tolerability. Clinical trial\ninformation: NCT05194982. Research Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.\nNSCLC(EGFR- NSCLC\nmut) (EGFRwt) (SCLC) (NPC) HNSCC\n(n=34)1 (n=42)2 (n=7) (n=24) (n=13)\nMedianpriortreatmentline 4(1-7) 2(1-8) 2(1-2) 3(1-9) 3(1-7)\n(range)\nBestoverallresponse,n3\ncPR 15 7 1 3 /\nPR4 6 10 0 8 1\nSD(nwithshrinkage) 10(10) 23(16) 5(4) 13(12) 9(8)\nPD 3 2 1 / 3\nORR5,% 61.8 40.5 14.3 45.8 7.7\n(95%CI) (43.6-77.8) (25.6-56.7) (0.4-57.9) (25.6- (0.2-36.0)\n67.2)\nDCR,% 91.2 95.2 85.7% 100% 76.9%\n(95%CI) (76.3-98.1) (83.8-99.4) (42.1- (85.8- (46.2-\n99.6) 100) 95.0)\n1AllhadpriorEGFRTKI,88%(30/34)hadprior3rdgenEGFRTKIand68%(23/34)hadpriorplatinum-\nbasedchemotherapy(PBC).2AllhadpriorPBC,88%(37/42)hadpriorPD-1/L1andPBC.3Only49pts\nhad1tumorassessment,including8EGFRmutNSCLC,19EGFRwtNSCLC,10NPC,8HNSCCand4\nSCLC.4IncludingptswhosePRswerenotyetconfirmedbutstillundertreatment.5During12/2022~01/\n2023,treatmentdelayof26pts(11NSCLC,3HNSCC,10NPC,2SCLC)duetoCOVID-19hada\nsignificantnegativeeffectontheir1stand/or2ndtumorassessment(s).\n\u00a92023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.\n331.111.300.291\nmorf\n6202\n,13\nyraunaJ\nno\n331.111.3.291\nyb\ngro.sbupocsa\nmorf\ndedaolnwoD\n.devreser\nsthgir\nllA\n.ygolocnO\nlacinilC\nfo\nyteicoS\nnaciremA\n6202\n\u00a9\nthgirypoC\n\n\n======================================================================\n\n======================================================================\nFULL TEXT FROM ref5.pdf:\n======================================================================\nHEMATOLOGIC MALIGNANCIES\u2014LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA\nTPS7595 Poster Session\nwaveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as\nmonotherapy or in combination in patients (pts) with aggressive and indolent B-cell\nmalignancies.\nPierLuigiZinzani,JiriMayer,OhadBenjamini,AlejandroBerkovits,IngridGlimelius,DonA.Stevens,\nArvindChaudhry,AhmetMuzafferDemir,Ramo\u00b4nGarciaSanz,WonSeogKim,FeiLi,JanuszHalka,\nAna Marin-Niebla, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Armando Santoro, Yixin Ren, Uzor Ogbu,\nPatriciaMarinello,WojciechJurczak;IRCCSAziendaOspedaliero-UniversitariadiBolognaIstitutodi\nEmatologia\u201cSera`gnoli\u201d,Bologna,Italy;FakultniNemocn</observation>"
        },
        {
            "role": "assistant",
            "content": "<execute>\nimport pdfplumber\nimport pandas as pd\nimport os\n\n# Get full text from ref5.pdf to complete the analysis\nref5_path = \"/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf\"\nwith pdfplumber.open(ref5_path) as pdf:\n    ref5_text = \"\"\n    for page in pdf.pages:\n        text = page.extract_text()\n        if text:\n            ref5_text += text + \"\\n\"\n\nprint(\"Ref5 full text last part:\")\nprint(ref5_text[-2000:])\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Ref5 full text last part:\netyrun-inphaseofZVincombinationwithnemtabrutinib,\nthenanadditional15patientswillreceivetheRP2Dofthecombination.PatientsincohortD(schedule\noptimization)willberandomized1:1toreceiveZV2.5mg/kgIVQ3W(arm1)orZV2.0mg/kgIVQ2/3W\n(arm 2). Patients in cohorts E and F (efficacy expansion) will receive the dose and schedule of ZV\ndetermined during schedule optimization. Each recipient of ZV or nemtabrutinib will receive the\nassignedinterventionuntildiseaseprogression,unacceptabletoxicity,orotherdiscontinuationcriteria\naremet.Tumorscanswillbeperformedatbaseline,thenQ12Wuptoweek108,thenQ24Wthereafter.\nAdverseevents(AEs)willbemonitoredandwillbegradedperNCICTCAEversion5.Theprimaryend\npoints are the safety and tolerability of ZV alone (cohort D) and in combination with nemtabrutinib\n(cohortC),andtheobjectiveresponserateofZValone(cohortsA,B,D,E,andF)andincombination\nwith nemtabrutinib (cohort C). The secondary end points are the duration of response of ZV alone\n(cohorts A, B, D, E, and F) and in combination with nemtabrutinib (cohort C) and the safety and\ntolerabilityofZValone(cohortsA,B,E,andF).Clinicaltrialinformation:NCT05458297. Research\nSponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.\nCohort InclusionCriteria n Treatment\nA R/RMCLafter$2therapiesincludingaBTKiandeitherreceivedor40 ZV2.5mg/kgIVQ3W\nwasineligibleforCAR-Tcelltherapy\nB R/RRTafter$1priortherapy 50\nC R/RMCLto$1priortherapyandnopriorexposuretononcovalent 45 ZV2.0to2.5mg/kgIVQ3W\nBTKi +\nNemtabrutinib65mgPOQD\nD R/RCLLorFLafter$2priortherapies 80 Randomized1:1toreceive:\nZV2.5mg/kgIVQ3W(arm1)\nor\nZV2.0mg/kgIVQ2/3W(arm2)\nE R/RFLafter$2priortherapies 30ZVondoseandscheduledetermined\nF R/RCLLafter$2priortherapies 30 incohortD\n\u00a92023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.\n331.111.300.291\nmorf\n6202\n,13\nyraunaJ\nno\n331.111.3.291\nyb\ngro.sbupocsa\nmorf\ndedaolnwoD\n.devreser\nsthgir\nllA\n.ygolocnO\nlacinilC\nfo\nyteicoS\nnaciremA\n6202\n\u00a9\nthgirypoC\n\n</observation>"
        },
        {
            "role": "assistant",
            "content": "Now I have all the necessary information. Let me extract the ADC data from each paper and create the CSV file:\n\n<execute>\nimport pandas as pd\nimport os\n\n# Create the output directory if it doesn't exist\noutput_dir = \"/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5\"\ntmp_dir = \"/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/adcdb_extract\"\n\nos.makedirs(output_dir, exist_ok=True)\nos.makedirs(tmp_dir, exist_ok=True)\n\n# Extracted ADC information from the papers\nadc_data = [\n    {\n        \"Paper\": \"ref2\",\n        \"ADC Name\": \"Zilovertamab vedotin (ZV)\",\n        \"mAb\": \"Humanized IgG1 monoclonal anti-ROR1\",\n        \"Linker\": \"Proteolytically cleavable linker\",\n        \"Payload\": \"Monomethyl auristatin E\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 2\"\n    },\n    {\n        \"Paper\": \"ref4\",\n        \"ADC Name\": \"BL-B01D1\",\n        \"mAb\": \"EGFRxHER3 bispecific antibody\",\n        \"Linker\": \"Cleavable linker\",\n        \"Payload\": \"Novel TOP-I inhibitor\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 1\"\n    },\n    {\n        \"Paper\": \"ref5\",\n        \"ADC Name\": \"Zilovertamab vedotin (ZV)\",\n        \"mAb\": \"Humanized IgG1 monoclonal anti-ROR1\",\n        \"Linker\": \"Proteolytically cleavable linker\",\n        \"Payload\": \"Monomethyl auristatin E\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 2\"\n    }\n]\n\n# Create DataFrame\ndf = pd.DataFrame(adc_data)\n\n# Display the data\nprint(\"Extracted ADC Information:\")\nprint(\"=\"*80)\nprint(df.to_string(index=False))\nprint(\"=\"*80)\n\n# Save to CSV\noutput_path = os.path.join(output_dir, \"adcdb_extract_1.csv\")\ndf.to_csv(output_path, index=False)\nprint(f\"\\nData saved to: {output_path}\")\n\n# Verify the saved file\nprint(\"\\nVerifying saved CSV file:\")\nsaved_df = pd.read_csv(output_path)\nprint(saved_df.to_string(index=False))\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Extracted ADC Information:\n================================================================================\nPaper                  ADC Name                                 mAb                           Linker                 Payload Conjugate Type DAR Drug Status\n ref2 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E            N/A N/A     Phase 2\n ref4                  BL-B01D1       EGFRxHER3 bispecific antibody                 Cleavable linker   Novel TOP-I inhibitor            N/A N/A     Phase 1\n ref5 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E            N/A N/A     Phase 2\n================================================================================\n\nData saved to: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv\n\nVerifying saved CSV file:\nPaper                  ADC Name                                 mAb                           Linker                 Payload  Conjugate Type  DAR Drug Status\n ref2 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E             NaN  NaN     Phase 2\n ref4                  BL-B01D1       EGFRxHER3 bispecific antibody                 Cleavable linker   Novel TOP-I inhibitor             NaN  NaN     Phase 1\n ref5 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E             NaN  NaN     Phase 2\n</observation>"
        },
        {
            "role": "assistant",
            "content": "<execute>\nimport pandas as pd\nimport os\n\n# Re-read with explicit NA handling to see actual file content\noutput_path = \"/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv\"\n\n# Read raw file content\nwith open(output_path, 'r') as f:\n    content = f.read()\n    print(\"Raw CSV file content:\")\n    print(\"=\"*80)\n    print(content)\n    print(\"=\"*80)\n\n# Re-save ensuring N/A is a string\nadc_data = [\n    {\n        \"Paper\": \"ref2\",\n        \"ADC Name\": \"Zilovertamab vedotin (ZV)\",\n        \"mAb\": \"Humanized IgG1 monoclonal anti-ROR1\",\n        \"Linker\": \"Proteolytically cleavable linker\",\n        \"Payload\": \"Monomethyl auristatin E\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 2\"\n    },\n    {\n        \"Paper\": \"ref4\",\n        \"ADC Name\": \"BL-B01D1\",\n        \"mAb\": \"EGFRxHER3 bispecific antibody\",\n        \"Linker\": \"Cleavable linker\",\n        \"Payload\": \"Novel TOP-I inhibitor\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 1\"\n    },\n    {\n        \"Paper\": \"ref5\",\n        \"ADC Name\": \"Zilovertamab vedotin (ZV)\",\n        \"mAb\": \"Humanized IgG1 monoclonal anti-ROR1\",\n        \"Linker\": \"Proteolytically cleavable linker\",\n        \"Payload\": \"Monomethyl auristatin E\",\n        \"Conjugate Type\": \"N/A\",\n        \"DAR\": \"N/A\",\n        \"Drug Status\": \"Phase 2\"\n    }\n]\n\ndf = pd.DataFrame(adc_data)\ndf.to_csv(output_path, index=False, na_rep=\"N/A\")\n\n# Verify again\nprint(\"\\nFinal verification - reading raw file:\")\nwith open(output_path, 'r') as f:\n    print(f.read())\n</execute>"
        },
        {
            "role": "user",
            "content": "<observation>Raw CSV file content:\n================================================================================\nPaper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status\nref2,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2\nref4,BL-B01D1,EGFRxHER3 bispecific antibody,Cleavable linker,Novel TOP-I inhibitor,N/A,N/A,Phase 1\nref5,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2\n\n================================================================================\n\nFinal verification - reading raw file:\nPaper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status\nref2,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2\nref4,BL-B01D1,EGFRxHER3 bispecific antibody,Cleavable linker,Novel TOP-I inhibitor,N/A,N/A,Phase 1\nref5,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2\n\n</observation>"
        },
        {
            "role": "assistant",
            "content": "..."
        },
        {
            "role": "user",
            "content": "Each response must include thinking process followed by either <execute> or <solution> tag. But there are no tags in the current response. Please follow the instruction, fix and regenerate the response again."
        },
        {
            "role": "assistant",
            "content": "**Updated Plan:**\n1. [\u2713] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)\n2. [\u2713] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf\n3. [\u2713] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)\n4. [\u2713] Create a structured dataset with the extracted information\n5. [\u2713] Save the results to the specified CSV file path\n\nThe task has been completed successfully. I've extracted ADC pharmacological information from all three PDF files and saved them to the specified CSV file. The CSV file contains the required columns (Paper, ADC Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status) with data for 3 ADCs:\n\n1. **Ref2**: Zilovertamab vedotin (ZV) - A Phase 2 ADC with humanized IgG1 anti-ROR1 mAb, proteolytically cleavable linker, and monomethyl auristatin E payload\n2. **Ref4**: BL-B01D1 - A Phase 1 first-in-class EGFRxHER3 bispecific ADC with cleavable linker and novel TOP-I inhibitor payload\n3. **Ref5**: Zilovertamab vedotin (ZV) - Same ADC as ref2, in Phase 2 study for B-cell malignancies\n\n<solution>\nSuccessfully extracted ADC pharmacological information from the three literature sources (ref2.pdf, ref4.pdf, ref5.pdf) and saved the results to `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv`.\n\nThe CSV file contains 3 ADC entries with the following extracted information:\n\n1. **ref2 - Zilovertamab vedotin (ZV)**: Humanized IgG1 monoclonal anti-ROR1 antibody, proteolytically cleavable linker, monomethyl auristatin E payload, Phase 2 status\n2. **ref4 - BL-B01D1**: EGFRxHER3 bispecific antibody, cleavable linker, novel TOP-I inhibitor payload, Phase 1 status  \n3. **ref5 - Zilovertamab vedotin (ZV)**: Humanized IgG1 monoclonal anti-ROR1 antibody, proteolytically cleavable linker, monomethyl auristatin E payload, Phase 2 status\n\nAll fields follow the required format with \"N/A\" for missing values (Conjugate Type and DAR were not specified in the literature).\n</solution>"
        }
    ]
}